Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development

The Prostate
G J KolvenbagK Gotting-Smith

Abstract

Bicalutamide (Casodex) is a new nonsteroidal antiandrogen developed for use in patients with prostate cancer. The efficacy and tolerability of bicalutamide as monotherapy and as combination therapy for patients with advanced prostate cancer have been evaluated in randomized clinical trials. Clinical trials are currently in progress to further evaluate bicalutamide as monotherapy in patients with advanced stages of disease and as adjuvant or first-line therapy in patients with early-stage disease. A review of published trials of bicalutamide focusing on dose-ranging investigations, phase II and phase III monotherapy trials, a phase III trial of combined androgen blockade, and a safety overview. In dose-ranging trials, bicalutamide doses of 10-200 elicited biochemical, objective, and subjective responses; higher bicalutamide doses (up to 600 mg) have also been evaluated. A 50-mg daily dose of bicalutamide was initially evaluated as monotherapy in phase II and phase III trials; in subsequent trials, a 150-mg daily dose was investigated. A 150-mg daily dose is considered to provide equivalent survival outcome compared with castration in patients with locally advanced prostate cancer, whereas the benefits of a better quality of life...Continue Reading

References

Aug 17, 1989·The New England Journal of Medicine·E D CrawfordP J Goodman
Jan 1, 1996·The Journal of Urology·D K Wysowski, J L Fourcroy
Jan 1, 1994·The Prostate. Supplement·G R Blackledge, K Lowery
Jan 1, 1996·Urology·G J Kolvenbag, G R Blackledge
Jan 1, 1996·European Urology·G R Blackledge
Apr 1, 1997·Urology·F H SchröderB Tribukait
Aug 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H I ScherM Schwartz

❮ Previous
Next ❯

Citations

Oct 4, 2012·Future Oncology·Alex RawlinsonRoger Kunkler
May 3, 2014·Acta Pharmacologica Sinica·Zhi-yun ZhangMing-wei Wang
Feb 28, 2013·Molecular Cancer Therapeutics·Yu Chi YangMarianne D Sadar
Jul 5, 2005·Expert Opinion on Investigational Drugs·P Schellhammer
Jan 11, 2012·Expert Opinion on Investigational Drugs·Deborah MukherjiJohann S De-Bono
Sep 1, 2009·Expert Opinion on Drug Discovery·Jeremy Orion Jones
Jan 9, 2016·Expert Opinion on Drug Safety·Kyrillos Guirguis
May 1, 2012·Seminars in Oncology Nursing·Judith J Smith, Barbara K Dunn
Sep 8, 2010·Seminars in Oncology·Karen A Johnson, Powel H Brown
Oct 17, 2013·Journal of Cellular Physiology·Min ShenQ Ping Dou
Oct 22, 2011·Bioorganic & Medicinal Chemistry·Yukihiro ItohYuichi Hashimoto
Sep 21, 2013·Journal of Medicinal Chemistry·Antonella PepeSanjay V Malhotra
Apr 30, 1999·The Prostate·G J Kolvenbag, A Nash
Nov 10, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard I Scher, Charles L Sawyers
Mar 30, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mark N Stein, Thomas L Jang
Mar 9, 2017·Journal of Medicinal Chemistry·Claudia FerroniGreta Varchi
Feb 19, 2010·The Cancer Journal·Ayca Gucalp, Tiffany A Traina
Oct 29, 2004·Clinical Pharmacokinetics·Ian D Cockshott
Dec 24, 2002·Prostate Cancer and Prostatic Diseases·G W Chodak, G J C M Kolvenbag
Nov 27, 2019·Prostate Cancer and Prostatic Diseases·Claudia KeschMartin E Gleave
May 20, 2020·Nature Communications·Arnaud BlommeHing Y Leung
Apr 22, 2016·World Journal of Gastroenterology : WJG·Gee Young YunKyung Hee Kim
Nov 26, 2016·Nature Reviews. Drug Discovery·Ashton C Lai, Craig M Crews
Nov 22, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mark N Stein, Thomas L Jang
Aug 29, 2018·MedChemComm·Bianca WiedemannDaniel Rauh
Mar 21, 2021·Nature Reviews. Urology·Keith T SchmidtWilliam D Figg
Jun 19, 2021·Expert Review of Medical Devices·Jette BloembergPaul Breedveld
Apr 19, 2018·Inorganic Chemistry·Xiaodong QinShaohua Gou

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.